Topics

Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents

08:05 EDT 3 Apr 2019 | FinanzNachrichten

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that AP...

Original Article: Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents

NEXT ARTICLE

More From BioPortfolio on "Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents"

Quick Search